Ironwood Pharma (IRWD) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
May 5, 2022 7:00 AM EDTLINZESS® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year
Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million
GAAP net income of $39 million and adjusted EBITDA of $58 million; ended Q1 2022 with $593 million in cash and cash equivalents
BOSTON--(BUSINESS... More
